Skip to main
CHRO
CHRO logo

CHRO Market Capitalization Overview

Market Cap: $10.68M as of Jul 3, 2025

$10.68M
Past Month+$4.63M (76.43%)
As of Jul 3, 2025, CHRO has a market capitalization of $10.68M. Over the past 30 days, its market cap has increased by 1,400.45%, while in the last 12 months, it has increased by 186.25%.

Market capitalization represents the total value of Chromocell Therapeutics Corp as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

CHRO Market Cap Formula = Stock Price * Shares Outstanding

The market cap of CHRO helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

CHRO Market Cap History

DateMarket CapChange
Jul 1, 2025$89.05M+1,400.45%
Jun 2, 2025$5.94M-18.40%
May 1, 2025$7.28M-7.41%
Apr 1, 2025$7.86M-38.64%
Mar 3, 2025$12.80M+3.29%
Feb 3, 2025$12.40M+194.45%
Jan 2, 2025$4.21M+8.94%

CHRO End of Year Market Cap History

DateMarket CapChange
2025$10.68M+186.25%
2024$3.73M

FAQs About Chromocell Therapeutics Corp (CHRO) Market Cap

As of Jul 3, 2025, the market capitalization of CHRO is $10.68M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Chromocell Therapeutics Corp’s market capitalization has increased by 76.43%, changing from $6.06M to $10.68M as of Jul 3, 2025.

In the last 3 months, Chromocell Therapeutics Corp’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Chromocell Therapeutics Corp’s market capitalization increased from – in January to $3.73M in December, reflecting a — change.

Chromocell Therapeutics Corp (CHRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.